The Bradykinin (BK) system has a very significant role in the regulation of blood pressure (BP). Hence, reduced activity of BK receptors mediated via decreased circulating endogenous kinin might explain the cause of high BP. This system also governs the activation of the angiotensin system at various axes in control of the physiological BP. The BK receptor antagonists can block the hypotensive action of angiotensin-converting enzyme inhibitors (ACEls) in hypertensive and normotensive animals. The hypotensive action of BK is highly increased with ACEIs or kininase II inhibitor treatment. The development of specific BK agonists may provide a new direction to explore the experimental approach for examining the role of BK in hypertension. the BK (Arg-Pro-Pro-gly-Phe-Ser-Pro-Phe-Arg), Kallidin (Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) and methionyl-Iysyl-Bk, (Met-Lys-Arg-Pro-Pro-Gly-Phe-Arg). Kallidin and methionyl-lysyl-BK are converted into BK by amino peptidases present in plasma and urine. BK is rapidly « 15 sec) inactivated by circulating kinases (6). Once BK is
Angiotensin-converting enzyme inhibitors are powerful BP-reducing agents in hypertensive and in normotensive subjects (1) (2) . These drugs are widely used as the most effective anti-hypertensive agents in patients with essential hypertension, as well as in those patients in whom the hypertension are not associated with raised activity of the rennin-angiotensin system (RAS) (3) . On the one hand, it has been indicated that captopril decreases proteinurea in hypertensive patients with renal disease by reducing angiotensin II formation (4) . On the other hand, their BP-Iowering property in hypertensive patients has been suggested to be due mainly to the blockade of angiotensin II release (5) which is considered as the prime mode of action of these substances. However, it is postulated that their mode of action may not be due solely to inhibition of ACE production. ACE is identical to kininase II, an enzyme that not only inhibits the conversion of angiotensin I to angiotensin II, but also protects the kallikrein-kinin system (KKS) by interfering with the biodegradation of the vasodepressor and diuretic polypeptide kinins (1) (2) . The present review aims at providing the role of BK in mediating hypotensive effect ofACEIs.
Formation and inactivation of bradykinin
Bradykinin, a pharmacologically active polypeptide, is a kinin which is released in the tissues and body fluids as a result of enzymatic action of kallikreins on kininogens. The kinins are released in the blood and body fluids, it may act on two BK receptors known as B I and B 2 • Kininogens are multifunctional proteins derived mainly from alpha-2 globulin. In humans, the two forms of kininogens are high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). These kininogens differ from each other in molecular weight, susceptibility to plasma and tissue kallikreins and in their physiological properties (7) . They are synthesized in the liver and circulate in the plasma and other body fluids.
There are two forms ofkaIlikreins known as tissue kallikrein and plasma kallikrein. Tissue kallikrein is found in various organs such as the kidney, heart and synovial tissue. The tissue kallikrein is synthesized in the cell as a precursor and converted into the active form by the cleavage of an amino terminal peptide (8) . Active tissue kallikrein acts on LMWK to release kallidin. Tissue and plasma kallikreins differ from one another in molecular weight, biological functions, physicochemical and immunological properties. The plasma kallikrein is present in circulation in an inactive form, which is known as prekallikrein or Fletcher factor. This inactive prekallikrein is converted to active kallikrein by activated Hageman factor (XIIa). In addition, plasma kallikrein is able to convert inactive factor XII to XlIa by positive feedback reaction (8) . The plasma prekallikrein and HMWK are present together in a complex form. Factor XIIa and factor XI circulate with HMWK in bound form. In this way, factor XI can be converted into factor XIa for the participation in intrinsic coagulation cascade. In immunological reactions, tissue proteoglycan and mast cell heparin might act as an initiating surface for initial activation of the Hageman factor.
The kininases, kinin inactivating enzymes, are present in the plasma, endothelial cells and in the tissues to regulate the physiological functions of the kinins in the body. These are known as kininase I, kininase II or angiotensin-converting enzyme (ACE) and encephalinase. In plasma, kininase I cleaves the C-terminal arginine of BK to form des-Arg9-BK. Kininase II causes inactivation of BK by releasing pentapeptide (Arg-Pro-Pro-gly-Pheo and tripeptide (Ser-Pro-Phe) fragments (7) . Fig. I shows the formation of BK
Pathophysiological roles of bradykinin system in hypertension Clinical hypertension
Hypertension is a major risk factor in the development of cardiovascular diseases, such as coronary heart disease, congestive heart failure and peripheral vascular and renal diseases. There is ample evidence documenting the role of BK in the pathogenesis of hypertension (9) (10) . The pharmacological actions of BK in regulation of systemic BP are vasodilation in most areas of circulation, reduction in total peripheral vascular resistance and regulation of sodium excretion from the kidney (11) . When BK is injected into the renal artery, it causes diuresis and natriuresis by increasing renal blood flow (12) . These actions of BK have been attributed to prostaglandin release in the renal circulation (13) . In 1934, Elliot and Nuzum had already noticed that hypertensive patients without clinically apparent renal disease have significantly low levels of urinary kallikrein than normotensive subjects (14) . This abnormality in human hypertension was not confirmed until 1971.
The role of KKS in hypertension was established by Margolius and co-investigators (15) (16) (17) with the observations that urinary kallikrein excretion is significantly reduced in hypertensive patients and hypertensive rats. This led to the suggestion that reduced urinary kallikrein excretion might result from a reduction in kinin generation in hypertensive situations. Kallikrein excretion in white hypertensive men was lower than that in white normotensives during normal sodium intake, but was not different from that in black hypertensives and black control subjects under the same conditions. The kallikrein levels in the urine of normotensive black subjects are significantly lower than those in normal white subjects. All groups have greater urinary kallikrein activity on a low-sodium diet vs an unrestricted sodium intake, but the increase in black hypertensives is small. Plasma rennin activity shows similar increments after sodium restriction in all groups. Similar results on reduced excretion of urinary kallikrein in black subjects were obtained (18) . Plasma kinins in clinical hypertension are known to be modulated by loss of sodium (19) (20) These findings strongly support the view that sodium intake can modulate the kinin system. Furthermore, patients with malignant essential hypertension excrete less urinary kallikrein than those with non-malignant essential hypertension and normotensive control subjects (21) . Some studies have reported that white patients with uncomplicated essential hypertension show normal kallikrein excretion rates with normal plasma renin activity and aldosterone (22) . Only hypertensives over 40 years of age excrete significantly lower urinary kallikrein (23) . Moreover, a Brazilian study recently showed lower urinary kallikrein activity in hypertensive patients than control subjects (24) . On the other hand, it is noted that hormone replacement therapy caused a significant rise in urinary kallikrein levels that might have a cardioprotective effect (25) .
It has been suggested that the race and the sodium intake in hypertension have greater influence upon kallikrein excretion (26-~S) . These investigators evaluated urinary kallikrein levels in large populations of hypertensive cases and their families. The result showed that whites excrete more kallikrein than blacks, and white hypertensives excrete less kallikrein than white normotensive individuals. All test groups had higher kallikrein excretion when kept on low sodium intake. Black hypertensives excreted less kallikrein than black normotensives during sodium reduction. Furthermore, families with reduced kallikrein excretion had higher BP than those with increased urinary kallikrein excretion. This could suggest a genetic defect in the renal kallikrein and/or the presence of higher amounts oftissue kallikrein inhibitor in certain races. An altered frequency of a promoter polymorphism ofkinin B 2 receptor gene in hypertensive African-Americans has been documented (29) . Also, pregnancy-induced hypertension has been suggested to be due to decreased kidney kallikrein excretion. This could be due to a lack of BP lowering factors in pregnancy which causes the rise in BP (30) . The identification ofa subset of subjects with genetically reduced kallikrein activity as a result of an amino acid mutation could facilitate analysis of the role of the kallikrein-kinin system in renal and vascular diseases (31) . Kallikrein excretion was decreased in hypertensive patients with mild renal insufficiency (32) . Although no significant difference in the urinary kallikrein excretion of patients with low-renin essential hypertension was found, hypertensive patients with mild renal insufficiency showed reduced urinary kallikrein excretion (32) . Patients with reduced glomerular filtration rates showed markedly decreased urinary kallikrein excretion, like those with hypertension (33) . Renal parenchymal diseases with hypertension, such as chronic glomerulonephritis, are associated with diminished kallikrein activity (32) . However, recent studies suggest a strong influence of urinary kallikrein excretion on the salt sensitivity of blood pressure in normotensive patients. In a randomized cross-over double-blind study, the urinary excretion of active kallikrein was significantly lower in salt-sensitive hypertensives than in salt-resistant hypertensive patients, and it showed an inverse correlation with plasma atrial natriuretic peptide levels. Thus, at least some of the hypertensive patients excrete lower levels of kallikrein without reduced renal function. Research on the systemic changes in kallikrein has provided further insight into the mechanisms of various hypertensive conditions. In this connection, it is known that kininogen levels and kinin-forming factors are reduced in essential and malignant hypertension (34) (35) . It may be that a deficiency of plasma HMWK due to a decrease in liver synthesis (which decreases kinin production) occurs in an individual who develops hypertension after mild exercise (36) . It is proposed that a deficiency in BK might be a significant factor in the pathophysiology of hypertension. In this regard, it is suggested that the role of renal BK is to excrete the excess of sodium. Therefore, a reduction in the generation of renal BK may be the cause in the development of hypertension as a result of the accumulation of sodium in the body (10) .
Antihypertensive action of angiotensin-converting enzyme (kininase II) inhibitors
The discovery of kininase II inhibitors came after the observations that various extracts from the venom of Viper Bothrops jaracara potentiated the actions of BK (37) . This property appeared to result from inhibiting the kininases responsible for BK biodegradation. In addition, Bakhle (38) reported this BK-potentiating agent can also inhibit the conversion of angiotensin I to Angiotensin II. Subsequently, it was discovered that the ACE is identical to kininase II, which causes release of angiotensin II on one hand, and on the other hand, it can also cause inactivation of BK (39) . On this principle, Ondetti et al. (40) synthesized an orally active agent (SQ, 14,225 or captopril). Since then numerous compounds belonging to this class have been developed which are under vigorous clinical evaluation. These ACE (kininase II) inhibitors have the unique property to cause reduction in BP not only in hypertensive human and animals, but also to reduce BP in normotensive individuals and animals (2) , whereas other groups of anti-hypertensive drugs are devoid of these dual properties. Captopril has been shown to be active in lowering BP in various hypertensive models (41) (42) (43) , and in essential hypertensive patients (44) . Administration of captopril (1.5 mg/kg i.v.) to normotensive mongrel dogs was associated with an increased renal blood flow despite a significant fall of 17 mmHg in mean arterial BP (45) . These investigators also observed an increased urinary kinin excretion which might be associated to the regulation of renal vasculature. Enalapril is known to possess hypotensive action in experimental and clinical hypertension (46) (47) . In conclusion, it seems that these drugs are able to reduce BP in physiological and pathological states. The reduction of physiological BP is suggestive that endogenous mediators of vasodilation might be potentiated in the presence of ACEIs, and the role of renin-angiotensin system in the long term BP regulation may be questionable with reference to the genesis of hypertension.
The mode of actions of ACEIs in normotensive and hypertensive conditions are not clearly described. However, it is documented that BP-lowering effects of ACEIs in hypertensive patients is mainly due to the blockade of angiotensin II formation (5) , and is partially due to protection of kinins. Masuda et al. (48) have proposed that both the reduced plasma angiotensin II and the increased plasma kinin may contribute to the hypotensive effect of ramipril in normal renin group, whereas anti-hypertensive action in low renin class should be considered to be mainly based on an increased plasma kinin levels. Aprotinin, a tissue kallikrein inhibitor, blocks the anti-hypertensive effect of captopril in patients with low and normal RAS having essential hypertension (49) . In addition, failure of captopril to lower BP in some hypertensive patients might reflect the blunted activity of KKS (50) . Determination of plasma and tissue kinin levels in the presence and in the absence of ACEIs in human could provide meaningful information concerning the status of KKS in the mode of action of ACEIs. Nevertheless, due to methodological artifacts the blood concentrations of kinins have been observed to be raised, unchanged or reduced after the administration of ACEIs (51) (52) . Thus, it is suggested that kinins participate in the BP regulation of ACEIs. However, other studies contradict this hypothesis, indicating that inhibition of KKS per se will often result in a reduction of stimulated renin activity, therefore, the measurement of kinins in the plasma cannot clarify the role of BK in ACE inhibition (5) . Moreover, reversal of hypotensive action of ACEIs by using specific kinin receptor antagonists may provide the most reliable direct evidence that kinins do play a role in the hypotension-induced by ACEIs.
Bradykinin receptor blockers and angiotensinconverting enzyme inhibitors
Currently, BK receptor antagonists are available as valuable tools for the evaluation of the biological functions of BK with special interest to the mode of action of ACEIs. Stewart and Vavrek (53) showed that BK antagonists inhibited the BP-lowering effect ofBK. In the rat, the fall in mean arterial BP induced by intra arterial (i.a) injections of BK was highly reduced during an i.a. infusion of BK antagonist (B43 10) (54) . A theoretical possibility exists that administration of BK antagonists should produce a rise in BP if the kinins are indeed mediators of BP regulation. In this regard, Carbonell and co-workers (55) demonstrated that treatment with high doses of a kinin antagonist produced an increase in BP in the rat. Thus, kinins have a major role in the control of normal BP. Furthermore, it has been demonstrated in acute experiments on spontaneously hypertensive rats that; (a) BK induced hypotension was greatly potentiated after captopril treatment, (b) hypotensive responses produced by BK and captopril were significantly antagonized in the presence of BK antagonist (B5630) and (3) heart rate did not change during administration of these agents (2).
CONCLUSION
Bradykinin system has an important role in the pathophysiology of hypertension. Treatment with Kininase II Inhibitors or ACEIs may cause activation of BK which could playa prime function in the mechanism of the anti-hypertensive action of these drugs. Furthermore, ACEIs may also cause activation of BK receptors.
